## ILMN: Illumina, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.6% in mid entry zone (3.0-6.0%), top quartile (86th pct) cross-sectional ranking. Short-term MRS_5 (4.7%) confirms momentum alignment. Strong momentum (+5.0% 5-day acceleration). Outperforming sector by 4.0%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($133.51)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Who Owns Illumina? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260103T020847 | Neutral | Relevance: 100%
- This article details the major shareholders of Illumina (NASDAQ: ILMN), a leading genomics tools company, highlighting the significant institutional ownership and recent adjustments by top investment firms. It also examines recent insider trades, which show a mixed pattern of small sales and modest director purchases. The analysis suggests that Illumina is viewed as a recovery story, with investors and insiders carefully positioning themselves.

**2. Illuminaâ€™s Crossroads: Genomics Pioneer Tests Investor Patience As Wall Street Reassesses The Story**
- Source: AD HOC NEWS | 20260104T185402 | Neutral | Relevance: 100%
- Illumina's stock has seen a slight dip amidst market caution, as the company works to resolve regulatory issues and refocus on its core sequencing growth. Investors are weighing whether the genomics pioneer is a turnaround success in the making or a cautionary tale, with sentiments shifting from earlier optimism. The market awaits clear signals regarding the divestiture of Grail, disciplined capital allocation, and re-accelerating sequencing demand to determine its future trajectory.

**3. Illumina (NASDAQ:ILMN) Lowered to "Hold" Rating by Zacks Research**
- Source: MarketBeat | 20260103T110847 | Neutral | Relevance: 100%
- Zacks Research has downgraded Illumina (NASDAQ:ILMN) from a "strong-buy" to a "hold" rating, aligning with the current consensus "Hold" rating and a price target of $118.31. Despite the downgrade, Illumina recently exceeded quarterly estimates with $1.34 EPS versus $1.16 expected and $1.08 billion in revenue, also issuing positive FY2025 guidance. The company holds a market capitalization of approximately $20.5 billion, with institutional investors owning about 89.42% of its stock.

**4. Illumina Inc.: Can the Genomics Pioneer Reinvent Itself for the AI Era?**
- Source: AD HOC NEWS | 20260103T080847 | Neutral | Relevance: 100%
- Illumina Inc. is striving to reinvent its genome sequencing platform for an AI-driven clinical market amidst competition and investor scrutiny. The company, which has been central to genomics for over a decade, faces challenges from rivals offering cheaper instruments and the need to integrate AI-ready genomic insights. Its success hinges on its ability to sustain technological leadership and evolve into a software-enabled data partner in the dynamic genomics landscape.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Guggenheim | $144 | $114 | +26% |
| 2025-12-22 | Canaccord Genui | $130 | $112 | +16% |
| 2025-12-15 | Barclays | $110 | $100 | +10% |
| 2025-12-15 | JP Morgan | $130 | $105 | +24% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Guggenheim | main | Buy |
| 2025-12-22 | Canaccord Genui | main | Hold |
| 2025-12-15 | Barclays | main | Underweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.06M) |
| Sells | 10 ($80.29M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Capital World Invest: 13.1% (+20.0%)
- Blackrock Inc.: 12.2% (-3.5%)
- Vanguard Group Inc: 9.6% (-3.5%)
- State Street Corpora: 3.9% (+6.8%)
- Sessa Capital IM, L.: 3.1% (-0.8%)

### Key Risks

1. Heavy insider selling: $80M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +5.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.62 indicates undervaluation relative to growth. Forward P/E 28.0x stretched relative to 7% growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($80.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.7B |
| Beta | 1.41 |
| 52W Range | $68.70 - $153.06 |
| Short Interest | 7.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.62 |
| Forward P/E | 28.0 |
| Current P/E | 30.0 |
| YoY Growth | 7.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.4% to 4.6% (+5.0% in 5 days), confirming momentum buildup. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 86th percentile. MRS_5 at 4.7% confirms short-term momentum alignment. Outperforming sector by 4.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +F0N (Breakout).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.60% (CS: 87) | Strong |
| RSI_14 | 67.4 | Neutral |
| MACD Histogram | -0.32 | Bearish |
| vs SMA20 | 1.057x | Above |
| vs SMA50 | 1.134x | Above |
| vs SMA200 | 1.425x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $141.33
- **Stop Loss:** $133.51 (5.5% risk)
- **Target:** $153.06 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 110
- **Position Value:** $15,546.30
- **Portfolio %:** 15.55%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-05 (Est: $1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.34 | +14.7% |
| 2025Q2 | $1.01 | $1.19 | +17.7% |
| 2025Q1 | $0.94 | $0.97 | +3.3% |
| 2024Q4 | $0.92 | $0.86 | -6.8% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_10*